TESLA WATCH: Elon Musk Pay Deal In Focus Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older cystic fibrosis treatment, Trikafta. Vertex Pharmaceuticals (VRTX) is working to shift patients to the newer triplet, Alyftrek. Together, Trikafta and Alyftrek brought in $2.9 billion in sales, topping projections for$2.86 billion, RBC Capital Markets analyst Brian Abrahams said. Sales of Alyftrek, by itself, came in at $247 million. That beat s ...